How do you pronounce Dabrafenib?
How do you pronounce Dabrafenib?
dabrafenib
- Genetic Implications:
- Pronunciation: da-braf-e-nib.
- Trade Name(s)
- Ther. Class. antineoplastics.
- Pharm. Class. kinase inhibitors.
How do you pronounce ipilimumab?
Pronunciation: (ih-pih-LIH-myoo-mab)
What is the side effect of plx4032?
The most common adverse reactions of any grade (≥ 30% in either study) in ZELBORAF-treated patients were arthralgia, rash, alopecia, fatigue, photosensitivity reaction, nausea, pruritus, and skin papilloma….Clinical Trials Experience.
| ADRs | Fatigue |
|---|---|
| Trial 1: Treatment – Naive Patients | 38 |
| 2 | |
| 33 | |
| 2 |
What does vemurafenib target?
Vemurafenib specifically targets the V600E mutated BRAF protein. The drug interferes with abnormal BRAF signals to slow or stop the out-of-control cell growth.
Where did the drug vemurafenib get its name?
The name “vemurafenib” comes from V 600 E mu tated B RAF in h ib ition. Vemurafenib received FDA approval for the treatment of late-stage melanoma on August 17, 2011, making it the first drug designed using fragment-based lead discovery to gain regulatory approval. Vemurafenib later received Health Canada approval on February 15, 2012.
What are the most common side effects of vemurafenib?
The BRIM-2 trial investigated 132 patients; the most common adverse events were arthralgia in 58% of patients, skin rash in 52%, and photosensitivity in 52%. In order to better manage side effects some form of dose modification was necessary in 45% of patients.
What are the mechanisms of resistance to vemurafenib?
Three mechanisms of resistance to vemurafenib (covering 40% of cases) have been discovered: Cancer cells begin to overexpress cell surface protein PDGFRB, creating an alternative survival pathway. A second oncogene called NRAS mutates, reactivating the normal BRAF survival pathway. Stromal cell secretion of hepatocyte growth factor (HGF).
How is vemurafenib used in the treatment of melanoma?
In a phase I clinical study, vemurafenib (then known as PLX4032) was able to reduce numbers of cancer cells in over half of a group of 16 patients with advanced melanoma. The treated group had a median increased survival time of 6 months over the control group.